Crispr Therapeutics (NASDAQ:CRSP) Lowered to Strong Sell at BidaskClub

BidaskClub downgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a sell rating to a strong sell rating in a research report released on Tuesday morning, BidAskClub reports.

A number of other equities research analysts have also recently weighed in on CRSP. TheStreet upgraded shares of Crispr Therapeutics from a d rating to a c rating in a report on Monday, October 28th. Needham & Company LLC restated a buy rating and issued a $84.00 price objective on shares of Crispr Therapeutics in a report on Monday, December 23rd. Canaccord Genuity upped their price objective on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a report on Wednesday, November 20th. Roth Capital upped their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Finally, Piper Jaffray Companies restated a buy rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a report on Monday, December 16th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $78.29.

Shares of CRSP opened at $55.80 on Tuesday. The stock has a market cap of $3.15 billion, a PE ratio of -121.30 and a beta of 3.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a fifty-two week low of $30.75 and a fifty-two week high of $74.00. The firm’s 50-day simple moving average is $57.63 and its two-hundred day simple moving average is $53.03.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $1.19. The business had revenue of $77.00 million for the quarter, compared to analysts’ expectations of $39.08 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business’s revenue was up 76900.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.92) earnings per share. Equities research analysts predict that Crispr Therapeutics will post 0.65 EPS for the current year.

In other news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at approximately $465,000. The disclosure for this sale can be found here. Corporate insiders own 21.40% of the company’s stock.

Several large investors have recently bought and sold shares of the company. NEXT Financial Group Inc lifted its position in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after purchasing an additional 549 shares during the period. Coastal Investment Advisors Inc. bought a new position in Crispr Therapeutics during the third quarter valued at approximately $26,000. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in Crispr Therapeutics during the fourth quarter valued at approximately $26,000. Webster Bank N. A. bought a new position in Crispr Therapeutics during the fourth quarter valued at approximately $26,000. Finally, Advisory Services Network LLC lifted its position in Crispr Therapeutics by 146.0% during the fourth quarter. Advisory Services Network LLC now owns 674 shares of the company’s stock valued at $41,000 after purchasing an additional 400 shares during the period. Hedge funds and other institutional investors own 50.01% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: What is the outlook for the FAANG stocks?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.